Novo Nordisk reported that strong prescription performance for its oral obesity therapy boosted demand, leading the company to revise expectations upward as it released earnings and guidance commentary tied to Wegovy pill uptake. The updates frame a less-negative trajectory for sales and profit compared with prior company guidance. The guidance shift reflects continuing traction in U.S. obesity pharmacotherapy adoption, even amid competitive dynamics from other incretin-based entrants. For investors, the main signal is that early momentum for the pill formulation is translating into forecastable commercial execution. This also highlights the market’s sensitivity to prescription pacing rather than only initial launch metrics, a key benchmark for follow-on manufacturing and distribution planning.